Findings suggest that the complement system plays a role in the onset of acute kidney injury in critically ill patients. Urinary Ba, a fragment of complement factor B, may be a biomarker and mediator ...
The FDA approved iptacopan for treatment of adults with paroxysmal nocturnal hemoglobinuria. Iptacopan (Fabhalta, Novartis) is an oral selective complement factor B inhibitor designed to be given as ...
A Hansoh Bio LLC, Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. patent details piperidinyl indole derivatives acting as complement factor B (CFB) inhibitors.
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial (NCT06209177) of ARO-CFB, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results